Treatment of Hematologic Disorders

Pharmacological Interventions

The American Society of Clinical Oncology recommends administering prednisone 0.5-1 mg/kg/day for treatment of hematologic disorders, with a strength of evidence rated as high for moderate to severe hemolysis (Grade 3) 1, 2
Rituximab may be considered for refractory cases of hematologic disorders, as suggested by the American Society of Clinical Oncology, and in cases of life-threatening hemolysis (Grade 4) 1, 2

When Autoimmune Hemolytic Anemia (AIHA) is suspected, a complete blood count with peripheral blood smear review, reticulocyte count, LDH, haptoglobin, and bilirubin levels, as well as cold agglutinin titer and Donath-Landsteiner test if specific types of AIHA are suspected, should be performed, as recommended by the American Society of Hematology 2
A negative Direct Antiglobulin Test (DAT) is required for the diagnosis of non-immune hemolytic conditions, such as atypical hemolytic uremic syndrome, according to the European Hematology Association 3
A complete clinical history with emphasis on medication exposure should be performed, and a peripheral blood smear should be reviewed to evaluate parameters of hemolysis, such as reticulocytes, LDH, and indirect bilirubin 4, 5, 6, 7

A positive Coombs test detects IgG bound to red blood cells (common in warm autoimmune hemolytic anemia) and complement bound to the surface of red blood cells, which is frequently seen in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma 4, 5, 6, 7
A direct Coombs test should be considered in patients with CLL, non-Hodgkin lymphoma, autoimmune disease, or those receiving associated medications, such as chemotherapy or erythropoiesis-stimulating agents (ESAs), due to the increased risk of thromboembolic events and hemolysis 5, 6, 8, 9

Early hematology consultation is recommended if hemolysis occurs during immunotherapy, due to the higher risk of immune-mediated hematologic toxicity, as supported by the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) guidelines 10
Patients with a history of autoimmune disease or those receiving medications such as talidomide or lenalidomida should undergo a Coombs test, as recommended by guidelines, due to the increased risk of thromboembolic events and hemolysis 5, 6, 9
The American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) recommend performing a Coombs test in patients with chronic lymphocytic leukemia (CLL) due to the high frequency of autoantibodies against red blood cells, with a strength of evidence rated as high 6, 7

In cases of life-threatening hemolysis (Grade 4), treatment options include methylprednisolone 1g IV daily for 3 days, plasma exchange, and rituximab in refractory cases, as suggested by the Journal of Clinical Oncology guidelines, with a strength of evidence rated as moderate 2